GYNECOLOGIC CANCERS

The combination of avutometinib with defactinib elicited high activity in patients with recurrent low-grade serous ovarian cancer, according to data from RAMP 201.

Adjuvant chemotherapy did not lead to survival improvements vs standard chemoradiotherapy alone in patients with locally advanced cervical cancer and resulted in more severe adverse events, according to OUTBACK trial data.

Additional findings from KEYNOTE-826 reveal no negative health-related quality-of-life impact when using pembrolizumab plus chemotherapy with or without bevacizumab.

Treatment with ceralasertib with and without olaparib showed promising signals of clinical activity in multiple rare gynecologic cancers, according to findings presented at the European Society for Medical Oncology Gynaecologic Cancers Congress 2023.

Significant rates of homologous recombination deficiency somatic gene mutations were found in patients with uterine serous cancer, resulting in possible implications for future testing and treatment for the patient population, according to the results of a research study.

At the Society of Gynecologic Oncology 2023 Annual Meeting, data showed that with a median follow-up of 25.8 months, the proportion of patients on Arm A of the NRG-GY017 trial of patients with cervical cancer with 2-year disease-free survival rate was 79% vs 59% in Arm B.

Findings from the patient-reported outcomes analysis of the phase 3 KEYNOTE-826 trial support the benefit of pembrolizumab in patients with recurrent, persistent, or metastatic cervical cancer.

In the NORA study, a 16% reduction in the risk of death was achieved with maintenance niraparib in patients with platinum-sensitive recurrent ovarian cancer.

David O’Malley, MD, discusses the background and updated results of the KEYNOTE-158 trial looking at pembrolizumab monotherapy in patients with advanced endometrial cancer.

CINtec PLUS Cytology is the only dual-stain triage test to be offered by BioReference Health LLC for patients with a high-risk human papillomavirus result.

Susana Banerjee, MBBS, PhD, discusses the significance of the long-term results of the MEDIOLA trial of patients with ovarian cancer.

During a Targeted Oncology case-based roundtable event, Paul D. DiSilvestro, MD, discussed the long-term results from the SOLO-1 trial of olaparib maintenance for patients with ovarian cancer. This is the first of 3 articles based on this event.

An expert details the currently available systemic therapies for patients with MMR-proficient metastatic endometrial cancer who experienced recurrent disease after platinum-based chemotherapy.

Dr Robert Holloway describes the presentation of a typical patient with metastatic endometrial cancer, and whether all patients receive MMR testing.

Robert Holloway, MD, presents the diagnosis and treatment regimen of a 71-year-old woman with mismatch repair-proficient (pMMR) metastatic endometrial cancer.

Anna Jo Bodurtha Smith, MD, discusses her research on insurance mediated disparities in gynecologic oncology.

Susana Banerjee, MBBS, PhD, discusses the updated results of the MEDIOLA trial of patients with ovarian cancer presented at the 2022 European Society for Medical Oncology Congress.

In a phase 1 study, a peptide conjugated vaccine showed potent immunogenicity and was able to induce functional T-cell responses in almost all vaccinated patients with HPV16-positive premalignancies.

During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.

Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.

Based on OS data from the phase 3 ENGOT-OV16/NOVA trial, the FDA has requested niraparib to have restricted use as a second-line maintenance therapy for patients without germline BRCA mutations.

Additional findings fro the phase 2 SOLO2 study shows that there is a need for research to determine the optimal strategy for patients who relapse after treatment with a PARP inhibitor.

Early results from the phase 1 JEWEL-101 study show XB002 is well-tolerated in patients with advanced solid tumors.

Amit M. Oza, MD, discusses progression-free survival findings from the phase 3 ARIEL4 clinical trial.

In an interview with Targeted Oncology™, Amit M. Oza, MD, discussed the overall survival analysis of the ARIEL4 clinical trial and unanswered questions about rucaparib treatment in certain ovarian cancer subgroups.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses how oncologists and health systems can overcome barriers to access to the best available care for patients with gynecologic cancers.

There is no single best treatment algorithm for ovarian cancer. Treatment decisions, which become increasingly complex with disease progression, are informed by several patient-specific clinicopathologic parameters and genomic results.

In the interview with Targeted Oncology, Anna Jo Bodurtha Smith, MD, discusses the effects various insurance types have on the quality of care of patients with gynecologic cancers.

Melissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.

For Gynecologic Cancer Awareness Month, Dr. Sonal Sura discusses the recent progress in the treatment of patients with cervical cancer.